ORION Biotech Catalyst Calendar
Menu

SEPN · Clinical results disclosure

SEP-479 · report Phase 1 data from both the SAD and MAD cohorts

  1. “in the first quarter of 2027” · Company press release and SEC Form 10-Q
  2. “late 2026 or early 2027” · SEC Form 10-Q
  3. “in late 2026 or early 2027” · SEC Exhibit 99.1

Said “in late 2026 / early 2027” on Jan 12, 2026; now “in the first quarter of 2027” on Aug 10, 2026; no results filing found as of Aug 10, 2026.

Septerna (SEPN) · Record SEPN-P1

Details

Septerna (SEPN) stated SEP-479 · report Phase 1 data from both the SAD and MAD cohorts: “in late 2026 / early 2027” (SEC Exhibit 99.1, filed ); the most recent dated timing wording located () was “in the first quarter of 2027” (Company press release · and SEC Form 10-Q · ).

Reviewed status as of : Timing changed.

On , timing wording changed from “late 2026 or early 2027” (SEC Form 10-Q · ) to “in the first quarter of 2027” (Company press release · ) and “in the first quarter of 2027” (SEC Form 10-Q · ).

When did Septerna say SEP-479 results would come?

On , Septerna wrote in its SEC Form 10-Q: “As a result, we expect to report Phase 1 data from both the SAD and MAD cohorts in the first quarter of 2027.” (Source)

Days left in the window the company stated: 163 · company’s wording: “first quarter of 2027”

Timeline card: SEP-479 · report Phase 1 data from both the SAD and MAD cohorts, latest timing wording as written, with dates and documents
Download card

Wording before and after

Before ·

We anticipate reporting data from the trial in late 2026 or early 2027.

Timing wording: “late 2026 or early 2027” · SEC Form 10-Q · SEC original

After ·

As a result, Septerna expects to report Phase 1 data from both the SAD and MAD cohorts in the first quarter of 2027.

Timing wording: “in the first quarter of 2027” · Company press release · Company original

As a result, we expect to report Phase 1 data from both the SAD and MAD cohorts in the first quarter of 2027.

Timing wording: “in the first quarter of 2027” · SEC Form 10-Q · SEC original

Watch this program: confirm your email to start one daily alert digest.

Or email ORION to ask for this Watch.

First stated window
“in late 2026 / early 2027”SEC Exhibit 99.1, filed
Disclosure date
None foundLast checked:

Timeline

How wording is compared

Equivalent half-year, quarter, and year notations are compared together while original wording stays visible. Qualifiers such as early, mid, late, and end remain distinct. A slash and or are compared together for two complete timing alternatives with explicit years. Each source is compared with the preceding checked date. Different wording in documents from the same day is shown separately, without assigning an order within that day. No comparison is made against a preceding date with different timing expressions. Status is set by founder review of the original filings.

DocumentDateEvent retainedExact company wordingReviewSource
SEC Exhibit 99.1Initial entry within checked sources: “in late 2026 / early 2027”Anticipate topline data in late 2026 / early 2027Checked by founderSEC original
SEC Exhibit 99.1Statement retained: “in late 2026 or early 2027”Septerna anticipates reporting data from the trial in late 2026 or early 2027.Checked by founderSEC original
SEC Form 10-QStatement retained: “late 2026 or early 2027”We anticipate reporting data from the trial in late 2026 or early 2027.Checked by founderSEC original
Company press releaseWording changed: “late 2026 or early 2027” → “in the first quarter of 2027”
Sources (2)
As a result, Septerna expects to report Phase 1 data from both the SAD and MAD cohorts in the first quarter of 2027.Checked by founderCompany original
SEC Form 10-QWording changed: “late 2026 or early 2027” → “in the first quarter of 2027”
Sources (2)
As a result, we expect to report Phase 1 data from both the SAD and MAD cohorts in the first quarter of 2027.Checked by founderSEC original
SEC Form 10-QContext disclosedTo fully characterize steady-state pharmacokinetics, dosing for the MAD cohorts will be extended to 14 days.
Part I, Item 2: Recent Developments, SEP-479 PTH1R Agonist Program; paragraph beginning Based on pharmacokinetic data (page 23)		Checked by founderSEC original

Sources

Last checked: . Compared by hand with the original filings by Jiwoo Seong (Woo).

Corrections

DateWhat changedWhyEvidence
Corrected the April 13 event label to Statement retained; removed that equivalent expression from Wording changes.The comparison treats late 2026 / early 2027 and late 2026 or early 2027 as equivalent timing alternatives. Original quotations are retained.January 12 SEC Exhibit 99.1 and April 13 SEC Exhibit 99.1, retained in First stated and Changes.
Added the August 10 10-Q sentence about extending MAD cohort dosing to 14 days as a Context disclosed row.Founder requested the exact company quotation and original filing link.https://www.sec.gov/Archives/edgar/data/1984086/000119312526342353/sepn-20260630.htm
Updated the Changes explanation to: Status is set by founder review of the original filings.The status is the founder-selected status retained in the reviewed record.Founder correction request on 2026-10-10; the reviewed Timing changed status is retained.

A correction is added here with its date, what changed, why, and the evidence. The earlier version is not deleted. Report an error: hello@orionbiotechai.com. If you want your name shown with the correction, include it; otherwise no name is shown.

Program file

Name as filed
SEP-479
Other names in filings
None listed
Indication in the filing
hypoparathyroidism
Trials named in the same filing
None listed
Latest timing wording
“As a result, we expect to report Phase 1 data from both the SAD and MAD cohorts in the first quarter of 2027.”
Source
10-Q · filed · SEC accepted · accession 0001193125-26-342353 · SEC original
Review
Checked by founder against the original filing
Last checked

Program SEPN-sep-479.

Septerna (SEPN) — SEP-479 · report Phase 1 data from both the SAD and MAD cohorts: “in late 2026 / early 2027” (SEC Exhibit 99.1 2026-01-12); statement retained “in late 2026 or early 2027” (2026-04-13); statement retained “late 2026 or early 2027” (2026-05-11); wording changed from “late 2026 or early 2027” (2026-05-11) to “in the first quarter of 2027” (2026-08-10); wording changed from “late 2026 or early 2027” (2026-05-11) to “in the first quarter of 2027” (2026-08-10). Status Timing changed, checked 2026-10-10. Sources: https://www.sec.gov/Archives/edgar/data/1984086/000119312526009864/d81130dex991.htm | https://www.sec.gov/Archives/edgar/data/1984086/000119312526152045/d57504dex991.htm | https://www.sec.gov/Archives/edgar/data/1984086/000119312526216759/sepn-20260331.htm | https://ir.septerna.com/news-releases/news-release-details/septerna-highlights-business-progress-and-reports-second-0 | https://www.sec.gov/Archives/edgar/data/1984086/000119312526342353/sepn-20260630.htm

Terms

First stated window
The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date
The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q
First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original
The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status
One of seven labels set by founder review of the original filings. Definitions: Methodology. Status definitions.